BIOCRYST PHARMACEUTICALS INC
NASDAQ: BCRX (BioCryst Pharmaceuticals, Inc.)
Kemas kini terakhir: 21 jam lalu8.22
-0.16 (-1.91%)
| Penutupan Terdahulu | 8.38 |
| Buka | 8.45 |
| Jumlah Dagangan | 4,424,258 |
| Purata Dagangan (3B) | 4,480,060 |
| Modal Pasaran | 2,061,581,184 |
| Harga / Pendapatan (P/E TTM) | 6.79 |
| Harga / Pendapatan (P/E Ke hadapan) | 454.55 |
| Harga / Jualan (P/S) | 3.10 |
| Harga / Buku (P/B) | 56.59 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 4 May 2026 |
| Margin Keuntungan | -10.62% |
| Margin Operasi (TTM) | 14.59% |
| EPS Cair (TTM) | -0.260 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 56.90% |
| Nisbah Semasa (MRQ) | 2.93 |
| Aliran Tunai Operasi (OCF TTM) | -25.85 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 42.90 M |
| Pulangan Atas Aset (ROA TTM) | 4.54% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Drug Manufacturers - Specialty & Generic (US) | Bercampur | Bercampur |
| Drug Manufacturers - Specialty & Generic (Global) | Bercampur | Bercampur | |
| Stok | BioCryst Pharmaceuticals, Inc. | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | -1.5 |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | -1.0 |
| Osilator Teknikal | 2.0 |
| Purata | 0.10 |
|
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology. |
|
| Sektor | Healthcare |
| Industri | Drug Manufacturers - Specialty & Generic |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 1.20% |
| % Dimiliki oleh Institusi | 87.44% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Deerfield Management Company, L.P. | 31 Dec 2025 | 14,341,000 |
| Julat 52 Minggu | ||
| Median | 13.00 (58.15%) | |
| Jumlah | 1 Beli | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| RBC Capital | 30 Jan 2026 | 13.00 (58.15%) | Beli | 6.58 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| STONEHOUSE JON P | - | 8.63 | -305,995 | -2,640,737 |
| Jumlah Keseluruhan Kuantiti Bersih | -305,995 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -2,640,737 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 8.63 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| STONEHOUSE JON P | Pengarah | 02 Mar 2026 | Jual automatik (-) | 305,995 | 8.63 | 2,640,737 |
| STONEHOUSE JON P | Pengarah | 02 Mar 2026 | Pelaksanaan pilihan | 305,995 | - | - |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 05 Feb 2026 | Pengumuman | BioCryst to Report Fourth Quarter 2025 Financial Results on February 26 |
| 05 Feb 2026 | Pengumuman | BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 23 Jan 2026 | Pengumuman | BioCryst Completes Acquisition of Astria Therapeutics, Expanding Leadership in Hereditary Angioedema |
| 12 Jan 2026 | Pengumuman | BioCryst Announces Preliminary Full Year 2025 ORLADEYO® (berotralstat) Net Revenue of $601 Million (+37 percent y-o-y), Beating Prior Guidance Range |
| 06 Jan 2026 | Pengumuman | BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 06 Jan 2026 | Pengumuman | BioCryst to Present at 44th Annual J.P. Morgan Healthcare Conference |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |